Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Mäkelä PH[au]:

Enterobacterial common antigen. Mäkelä PH et al. Bacteriol Rev. (1976)

Vaccines, coming of age after 200 years. Mäkelä PH et al. FEMS Microbiol Rev. (2000)

Evolution of conjugate vaccines. Mäkelä PH et al. Expert Rev Vaccines. (2002)

Search results

Items: 1 to 50 of 268

1.

Serotype-specific hyporesponsiveness to pneumococcal conjugate vaccine in infants carrying pneumococcus at the time of vaccination.

Väkeväinen M, Soininen A, Lucero M, Nohynek H, Auranen K, Mäkelä PH, Williams G, Käyhty H; ARIVAC Consortium.

J Pediatr. 2010 Nov;157(5):778-83.e1. doi: 10.1016/j.jpeds.2010.04.071. Epub 2010 Jun 14.

PMID:
20547399
2.

Modelling multi-type transmission of pneumococcal carriage in Bangladeshi families.

Erästö P, Hoti F, Granat SM, Mia Z, Mäkelä PH, Auranen K.

Epidemiol Infect. 2010 Jun;138(6):861-72. doi: 10.1017/S0950268809991415. Epub 2009 Dec 17.

PMID:
20018129
3.

Evolution of the capsular regulatory genes in Streptococcus pneumoniae.

Varvio SL, Auranen K, Arjas E, Mäkelä PH.

J Infect Dis. 2009 Oct 1;200(7):1144-51. doi: 10.1086/605651.

PMID:
19705970
4.

Epidemiological evidence for serotype-independent acquired immunity to pneumococcal carriage.

Granat SM, Ollgren J, Herva E, Mia Z, Auranen K, Mäkelä PH.

J Infect Dis. 2009 Jul 1;200(1):99-106. doi: 10.1086/599364.

PMID:
19469705
5.

Pneumococcal vaccination in the elderly: an underused option?

Honkanen PO, Mäkelä PH.

BioDrugs. 1999 Jul;12(1):19-25.

PMID:
18031159
6.

Immunogenicity and reactogenicity of 23-valent pneumococcal polysaccharide vaccine among pregnant Filipino women and placental transfer of antibodies.

Quiambao BP, Nohynek HM, Käyhty H, Ollgren JP, Gozum LS, Gepanayao CP, Soriano VC, Makela PH.

Vaccine. 2007 May 30;25(22):4470-7. Epub 2007 Mar 28.

PMID:
17442467
7.

Longitudinal study on pneumococcal carriage during the first year of life in Bangladesh.

Granat SM, Mia Z, Ollgren J, Herva E, Das M, Piirainen L, Auranen K, Mäkelä PH.

Pediatr Infect Dis J. 2007 Apr;26(4):319-24.

PMID:
17414395
8.

The value of nasopharyngeal culture in predicting the etiology of acute otitis media in children less than two years of age.

Syrjänen RK, Herva EE, Mäkelä PH, Puhakka HJ, Auranen KJ, Takala AK, Kilpi TM.

Pediatr Infect Dis J. 2006 Nov;25(11):1032-6.

PMID:
17072126
9.

Field evaluation of the chessboard modification for serotyping of Streptococcus pneumoniae in a small laboratory in Bangladesh.

Herva E, Granat S, Mia Z, Ollgren J, Piirainen L, Mäkelä PH.

Am J Trop Med Hyg. 2006 May;74(5):863-7.

PMID:
16687694
10.

[Health, well being, peace and safety are closely connected to each other].

Mäkelä PH.

Duodecim. 2006;122(1):7-8. Finnish. No abstract available.

PMID:
16509186
11.

Pneumococcal acute otitis media in relation to pneumococcal nasopharyngeal carriage.

Syrjänen RK, Auranen KJ, Leino TM, Kilpi TM, Mäkelä PH.

Pediatr Infect Dis J. 2005 Sep;24(9):801-6.

PMID:
16148847
12.
13.

Vaccinovigilance in Europe--need for timeliness, standardization and resources.

Lankinen KS, Pastila S, Kilpi T, Nohynek H, Mäkelä PH, Olin P.

Bull World Health Organ. 2004 Nov;82(11):828-35. Epub 2004 Dec 14.

14.

Invasiveness of serotypes and clones of Streptococcus pneumoniae among children in Finland.

Hanage WP, Kaijalainen TH, Syrjänen RK, Auranen K, Leinonen M, Mäkelä PH, Spratt BG.

Infect Immun. 2005 Jan;73(1):431-5.

15.

Indirect protection obtained by Haemophilus influenzae type b vaccination: analysis in a structured population model.

Leino T, Takala T, Auranen K, Mäkelä PH, Takala AK.

Epidemiol Infect. 2004 Oct;132(5):959-66.

16.

Modelling transmission, immunity and disease of Haemophilus influenzae type b in a structured population.

Auranen K, Eichner M, Leino T, Takala AK, Mäkelä PH, Takala T.

Epidemiol Infect. 2004 Oct;132(5):947-57.

17.

DNA immunization followed by a viral vector booster in a Chlamydia pneumoniae mouse model.

Penttilä T, Tammiruusu A, Liljeström P, Sarvas M, Mäkelä PH, Vuola JM, Puolakkainen M.

Vaccine. 2004 Sep 3;22(25-26):3386-94.

PMID:
15308363
18.

Concentration of antipneumococcal antibodies as a serological correlate of protection: an application to acute otitis media.

Jokinen JT, Ahman H, Kilpi TM, Mäkelä PH, Käyhty MH.

J Infect Dis. 2004 Aug 1;190(3):545-50. Epub 2004 Jul 2.

PMID:
15243930
19.

Predicting meningococcal disease outbreaks in structured populations.

Ranta J, Mäkelä PH, Arjas E.

Stat Med. 2004 Mar 30;23(6):927-45.

PMID:
15027081
20.

Does the presence of pneumococcal DNA in middle-ear fluid indicate pneumococcal etiology in acute otitis media?

Palmu AA, Saukkoriipi PA, Lahdenkari MI, Kuisma LK, Makela PH, Kilpi TM, Leinonen M.

J Infect Dis. 2004 Mar 1;189(5):775-84. Epub 2004 Feb 16.

PMID:
14976593
21.

Association of clinical signs and symptoms with bacterial findings in acute otitis media.

Palmu AA, Herva E, Savolainen H, Karma P, Mäkelä PH, Kilpi TM.

Clin Infect Dis. 2004 Jan 15;38(2):234-42. Epub 2003 Dec 19.

PMID:
14699456
22.

Ability of pneumococcal serotypes and clones to cause acute otitis media: implications for the prevention of otitis media by conjugate vaccines.

Hanage WP, Auranen K, Syrjänen R, Herva E, Mäkelä PH, Kilpi T, Spratt BG.

Infect Immun. 2004 Jan;72(1):76-81.

23.

Long-term persistence of immunity after immunisation with Haemophilus influenzae type b conjugate vaccine.

Mäkelä PH, Käyhty H, Leino T, Auranen K, Peltola H, Ekström N, Eskola J.

Vaccine. 2003 Dec 12;22(2):287-92.

PMID:
14615157
24.

Protective efficacy of a second pneumococcal conjugate vaccine against pneumococcal acute otitis media in infants and children: randomized, controlled trial of a 7-valent pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine in 1666 children.

Kilpi T, Ahman H, Jokinen J, Lankinen KS, Palmu A, Savolainen H, Grönholm M, Leinonen M, Hovi T, Eskola J, Käyhty H, Bohidar N, Sadoff JC, Mäkelä PH; Finnish Otitis Media Study Group.

Clin Infect Dis. 2003 Nov 1;37(9):1155-64. Epub 2003 Oct 7.

PMID:
14557958
25.

Conjugate vaccines--a breakthrough in vaccine development.

Mäkelä PH.

Southeast Asian J Trop Med Public Health. 2003 Jun;34(2):249-53. Review.

PMID:
12971544
26.

Anti-PsaA and the risk of pneumococcal AOM and carriage.

Rapola S, Jäntti V, Eerola M, Mäkelä PH, Käyhty H, Kilpi T.

Vaccine. 2003 Sep 8;21(25-26):3608-13.

PMID:
12922089
27.

Evolution of conjugate vaccines.

Mäkelä PH, Käyhty H.

Expert Rev Vaccines. 2002 Oct;1(3):399-410. Review.

PMID:
12901578
28.

Maternal immunization with pneumococcal polysaccharide vaccine in the Philippines.

Quiambao BP, Nohynek H, Käyhty H, Ollgren J, Gozum L, Gepanayao CP, Soriano V, Mäkela PH.

Vaccine. 2003 Jul 28;21(24):3451-4.

PMID:
12850358
30.

Haemophilus influenzae type b and cross-reactive antigens in natural Hib infection dynamics; modelling in two populations.

Leino T, Auranen K, Mäkelä PH, Käyhty H, Ramsay M, Slack M, Takala AK.

Epidemiol Infect. 2002 Aug;129(1):73-83.

31.

Antibody response to pneumococcal capsular polysaccharides in children with acute otitis media.

Soininen A, Lahdenkari M, Kilpi T, Mäkelä PH, Käyhty H.

Pediatr Infect Dis J. 2002 Mar;21(3):186-92.

PMID:
12005079
32.

Diagnosis of pneumococcal pneumonia.

Leinonen M, Mäkelä PH.

Clin Infect Dis. 2001 Oct 15;33(8):1440-1. No abstract available.

PMID:
11565089
33.

Do antibodies to pneumococcal surface adhesin a prevent pneumococcal involvement in acute otitis media?

Rapola S, Kilpi T, Lahdenkari M, Takala AK, Mäkelä PH, Käyhty H.

J Infect Dis. 2001 Sep 1;184(5):577-81. Epub 2001 Jul 30.

PMID:
11494164
34.

Antibody response to the pneumococcal proteins pneumococcal surface adhesin A and pneumolysin in children with acute otitis media.

Rapola S, Kilpi T, Lahdenkari M, Mäkelä PH, Käyhty H.

Pediatr Infect Dis J. 2001 May;20(5):482-7.

PMID:
11368104
35.

Microbial etiology of community-acquired pneumonia in the adult population of 4 municipalities in eastern Finland.

Jokinen C, Heiskanen L, Juvonen H, Kallinen S, Kleemola M, Koskela M, Leinonen M, Rönnberg PR, Saikku P, Stén M, Tarkiainen A, Tukiainen H, Pyörälä K, Mäkelä PH.

Clin Infect Dis. 2001 Apr 15;32(8):1141-54. Epub 2001 Mar 23.

PMID:
11283803
36.

Dynamics of natural immunity caused by subclinical infections, case study on Haemophilus influenzae type b (Hib).

Leino T, Auranen K, Mäkelä PH, Käyhty H, Takala AK.

Epidemiol Infect. 2000 Dec;125(3):583-91.

37.

Efficacy of a pneumococcal conjugate vaccine against acute otitis media.

Eskola J, Kilpi T, Palmu A, Jokinen J, Haapakoski J, Herva E, Takala A, Käyhty H, Karma P, Kohberger R, Siber G, Mäkelä PH; Finnish Otitis Media Study Group.

N Engl J Med. 2001 Feb 8;344(6):403-9.

38.

Immunity to Chlamydia pneumoniae induced by vaccination with DNA vectors expressing a cytoplasmic protein (Hsp60) or outer membrane proteins (MOMP and Omp2).

Penttilä T, Vuola JM, Puurula V, Anttila M, Sarvas M, Rautonen N, Mäkelä PH, Puolakkainen M.

Vaccine. 2000 Dec 8;19(9-10):1256-65.

PMID:
11137265
39.

Incidence of invasive Haemophilus influenzae type b infections in Filipino children.

Lupisan SP, Herva E, Nohynek H, Lucero MG, Sombrero LT, Quiambao BP, Abucejo PE, Arcay J, Mäkelä PH, Ruutu P.

Pediatr Infect Dis J. 2000 Oct;19(10):1020-2. No abstract available.

PMID:
11055611
40.

Predicting the course of meningococcal disease outbreaks in closed subpopulations.

Ranta J, Mäkelä PH, Takala A, Arjas E.

Epidemiol Infect. 1999 Dec;123(3):359-71.

41.

Vaccination against infections by Chlamydia pneumoniae.

Puolakkainen M, Mäkelä PH.

C R Acad Sci III. 1999 Nov;322(11):973-8. Review.

PMID:
10646092
42.

Vaccines, coming of age after 200 years.

Mäkelä PH.

FEMS Microbiol Rev. 2000 Jan;24(1):9-20. Review.

43.
44.

Depletion of CD8+ cells abolishes memory in acquired immunity against Chlamydia pneumoniae in BALB/c mice.

Penttilä JM, Anttila M, Varkila K, Puolakkainen M, Sarvas M, Mäkelä PH, Rautonen N.

Immunology. 1999 Jul;97(3):490-6.

45.

Prognosis after community-acquired pneumonia in the elderly: a population-based 12-year follow-up study.

Koivula I, Stén M, Mäkelä PH.

Arch Intern Med. 1999 Jul 26;159(14):1550-5.

PMID:
10421277
46.

The infant rat model adapted to evaluate human sera for protective immunity to group B meningococci.

Toropainen M, Käyhty H, Saarinen L, Rosenqvist E, Høiby EA, Wedege E, Michaelsen T, Mäkelä PH.

Vaccine. 1999 Jun 4;17(20-21):2677-89.

PMID:
10418919
47.

Incremental effectiveness of pneumococcal vaccine on simultaneously administered influenza vaccine in preventing pneumonia and pneumococcal pneumonia among persons aged 65 years or older.

Honkanen PO, Keistinen T, Miettinen L, Herva E, Sankilampi U, Läärä E, Leinonen M, Kivelä SL, Mäkelä PH.

Vaccine. 1999 Jun 4;17(20-21):2493-500.

PMID:
10418894
48.

Is cardiovascular disease preventable by vaccination?

Mäkelä PH.

Ann Med. 1999 Feb;31(1):61-5. Review.

PMID:
10219715
49.

Homing potentials of circulating antibody-secreting cells after administration of oral or parenteral protein or polysaccharide vaccine in humans.

Kantele A, Westerholm M, Kantele JM, Mäkelä PH, Savilahti E.

Vaccine. 1999 Jan 21;17(3):229-36.

PMID:
9987158
50.

Etiology of childhood pneumonia: serologic results of a prospective, population-based study.

Heiskanen-Kosma T, Korppi M, Jokinen C, Kurki S, Heiskanen L, Juvonen H, Kallinen S, Stén M, Tarkiainen A, Rönnberg PR, Kleemola M, Mäkelä PH, Leinonen M.

Pediatr Infect Dis J. 1998 Nov;17(11):986-91.

PMID:
9849979

Supplemental Content

Loading ...
Support Center